AMLX Amylyx Pharmaceuticals, Inc.
AMLX Amylyx Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
POC $13.99 · VWAP $20.26 · +30.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 3 others sold $2.9M, Sep 14
Coverage
1 watchlist
AMLX Price Structure
Loading timeframes…
Peers
Every watchlist AMLX belongs to, members best 30-day change first — AMLX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.39, net income -$43M (SEC filing). Across the print the stock moved +4.4% (close before → first close after).
full note →Against street estimates
How AMLX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
AMLX research tape
66 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.